Beta blocker therapy in African American patients with heart failure

Heart Failure Reviews

Volumn 9, Issue 2, 2004, Pages 161-167

  Goldstein, Sidney ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

African Americans; Beta blockers; Heart failure

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUCINDOLOL; CARVEDILOL; CYTOCHROME P450 2D6; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLYCOPROTEIN P; HYDRALAZINE; ISOSORBIDE DINITRATE; METOPROLOL; MOXONIDINE; OMEPRAZOLE; PLACEBO; WARFARIN;

AFRICAN AMERICAN; ARTICLE; CARDIOVASCULAR RISK; CAUCASIAN; CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; DIABETES MELLITUS; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG TRANSPORT; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INCIDENCE; MORBIDITY; RACE DIFFERENCE; SURVIVAL;

ADRENERGIC BETA-ANTAGONISTS; AFRICAN AMERICANS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOLOGICAL TRANSPORT; CARBAZOLES; ENDOTHELIUM, VASCULAR; HEART FAILURE, CONGESTIVE; HUMANS; PROPANOLAMINES; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ADRENERGIC;

EID: 8444231618     PISSN: 13824147     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:HREV.0000046371.67163.a4     Document Type: Article

References (24)

1. Gillum RF. The epidemiology of cardiovascular disease in Black Americans. New Engl J Med 1996;335:1597-1599.
2. Gillum RF. Heart failure in the United States 1970-1985. Am Heart J 1987; 113:1043-1045.
3. Centers for Disease Control. 1998 changes in mortality from heart failure-United States. Mor Mortal Wkly 1980-1995; Re. 47(30):
4. The SOLVD Investigators. Effects of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-691.
5. Dries DL, Exner DV, Gersh BJ, Cooper HA, et al. Racial differences in the outcome of left ventricular dysfunction. N Engl J Med 1999 ;340:609-616.
6. ALLHAT Officers and Coordinators for ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. JAMA 2002;288:2981-2997.
7. Carson P, Ziesche S, Johnson G, Cohn JN. Racial differences in response to therapy for heart failure: Analysis of the vasodilator - Heart failure trials. J of Cardiac Failure 1999;5:178-187.
8. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-1351
9. Packer M, Coats AJS, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-1658.
10. Merit-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). Lancet 1999;353:2001-2007.
11. The Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. New Engl J Med 2001;344:1659-1667.
12. Yancy CW, Fowler MB, Colucci WS, et al. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. New Engl J Med 2001;344:1651-1658.
13. Goldstein S, Deedwania P, Gottlieb S, Wikstrand J for the MERIT-HF Study Group. Metoprolol CR/XL in black patients with heart failure (from the metoprolol CR/XL randomized intervention trial in chronic heart failure). Am J Cardiol 2003;92:478-480.
14. Plehn JF, Krause-Steinrauf H, Anand IS, Gottleib S, O'Connor CM, Silver M, White M, Carson. Effect of race on cause specific mortality in BEST. Circulation 2000;102:II-779.
15. Eichhorn EJ, Domanski MJ, et al. Hemodynamic functional and neurohormonal responses to beta-blockade in black vs. non-black patients in BEST. Circulation 2000;102:II-778.
16. Eichhorn EJ, Domanski MJ, Adams K, Anderson JL Bristow MR Carson P, Yancy C, Krause-Steinrauf H. Effect of Beta-Blockade on Mortality in African Americans: The Beta-blocker evaluation survival trial. Circulation 2000;102:II-778.
17. Swedberg K, Bristow MR, Cohn JN, et al. The effects of moxonidine SR, an imidazoline agonist, on plasma norepinephrine in patients with congestive heart failure. Circulation 1996;94:690-697.
18. Yancy CW. Heart failure therapy in blacks: Same or different illness? In: Willenheimer R, Swedberg K, eds. Tailoring Heart Failure Therapy 1st edn. A Martin Dunitz Book, Lund: Taylor&Francis, 2003;55-72.
19. Xie HG, Kim RA, Wood AJ, Stein CM. Molecular basis of ethnic differences n drug disposition and response. Annu Rev Phamacol Toxicol 2001;41:815-850.
20. Small KM, Forbes SL, Rhaman FF, Bridges KM, Ligett SB. A four amino acid deletion polymorphism in the third intracellular loop of the human alpha 2c-adrenergic receptor confers impaired coupling to multiple effectors J Bio Chem 2000;275:23059-23064.
21. Borjesson M, Magnusson Y, Andersson B. A novel polymorphism in the gene coding for the beta-1 receptor associated with survival in patients with heart failure. JACC 1999;33:261A.
22. Johnson JA, Burlew BS, Stiles RN. Racial differences in beta adrenoreceptor mediated responsiveness. J Cardiovasc Pharmacol 1995;25:90-96.
23. Stein CM, Lang CC, Nelson R, Brown M, Wood AJJ. Vasodilation in Black Americans: Attenuated nitric oxide-mediated responses. Clin Pharmacol Ther 1997;62:436-443.
24. Cardillo C, Kilcone CM, Cannon III RO, Panza JA Attenuation of cylic nucleotide - mediated smooth muscle relaxation in blacks as a cause of racial differences in vasodilator function. Circulation 1999 99:90-95.